Click image to enlarge
The Human Bone Marker Panel II Base Kit provides basic components for the quantitative determination of both natural and recombinant human osteocalcin (OCL), osteonectin (ONN), and osteopontin (OPN) in serum and plasma. Base kits generally include only MSD plates coated with the capture antibody, SULFO-TAG-labeled antibody, and MSD proprietary read buffer. (See product insert for a list of kit components). Base kits are most commonly used for high-throughput screening and assay development.
-
-
Specifications
-
-
Documentation
-
References
Application(s)
|
|
Bone Disorders
|
|
Analyte(s)
|
|
Osteocalcin, Osteonectin, Osteopontin
|
|
Species
|
|
Human
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
Plate Type
|
|
96-well
|
|
Capture Antibody
|
|
Osteocalcin: Mouse Monoclonal Osteonectin: Goat Polyclonal Osteopontin: Goat Polyclonal
|
|
Detection Antibody
|
|
Osteocalcin: Mouse Monoclonal Osteonectin: Mouse Monoclonal Osteopontin: Goat Polyclonal
|
|
LLOD (Sensitivity)
|
|
Osteocalcin: 0.023 ng/mL Osteonectin: 2.6 ng/mL Osteopontin: 0.05 ng/mL
|
|
Dynamic Range
|
|
Osteocalcin: 0.023 - 200 ng/mL Osteonectin: 2.6 - 2000 ng/mL Osteopontin: 0.05 - 200 ng/mL
|
|
Sample Type
|
|
Serum, Plasma
|
|
Recombinant standards
|
|
Osteocalcin: Synthetic Human Osteocalcin (aa1-49) Osteonectin: Protein isolated from thrombin-activated human platelets Osteopontin: Recombinant human osteopontin, his-tagged
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
2-8 °C
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes.
|
|
|
|
Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats.
|
|
|
|
Assessment of cisplatin-induced kidney injury using an integrated rodent platform.
|
|
|
|
Early prediction of polymyxin-induced nephrotoxicity with next generation urinary kidney injury biomarkers.
|
|
|
|
View All
|
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters